NovoMix 70

NovoMix 70 is a biphasic insulin analogue suspension developed and marketed by Novo Nordisk. It consists of a mixture of 70% soluble insulin aspart, a rapid-acting insulin analogue, and 30% protamine-crystallized insulin aspart, an intermediate-acting form. This specific 70/30 ratio provides a higher proportion of rapid-acting insulin compared to the more common NovoMix 30 formulation, making it particularly effective for controlling postprandial glucose excursions while still providing a basal insulin component. The drug acts as an agonist at the insulin receptor, facilitating glucose uptake into peripheral tissues such as skeletal muscle and fat, and inhibiting hepatic glucose production. It is indicated for the treatment of diabetes mellitus in adults, including type 2 diabetes, and is typically administered via subcutaneous injection using prefilled pens or cartridges.

Brand names

NovoMix 70NovoMix70NovoMix-70

Other names

biphasic insulin aspart 70biphasic insulin aspart 70/30